Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
Switch to another antipsychotic may leads to lower tardive dyskinesia: no clinically important improvement compared with antipsychotic cessation (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Global state: Not improved or worsened ‐ medium term Dichotomised Montgomery‐Asberg Depression Rating Scale (MDRS) · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Not improved or worsened ‐ medium termDichotomised… compared with PLACEBO (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Relapse ‐ long termClinical judgement compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: Death ‐ long termOccurrences of death · patients with schizophrenia
ORAL FLUPHENAZINE showed no clear difference in adverse effects: Death ‐ long termOccurrences of death compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (akathisia) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
COMPARISON 1: CBT+ STANDARD CARE showed no clear difference in global state: 1a. Relapse ‐ long term compared with STANDARD CARE ALONE (low certainty).
1 finding from 1 review
Global state: 2. Clinically important change (no improvement) ‐ long term · patients with schizophrenia
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes global state: 2. Clinically important change (no improvement) ‐ long… compared with STANDARD CARE ALONE (very low certainty).
1 finding from 1 review
Mental state: General ‐ clinically important change (no improvement) · patients with schizophrenia
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes mental state: General ‐ clinically important change (no improvement)… compared with STANDARD CARE ALONE (very low certainty).
1 finding from 1 review
Adverse events experienced at short or long term ‐ general adverse events 24 weeks' · patients with schizophrenia
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes adverse events: General: any adverse event compared with STANDARD CARE ALONE (very low certainty).
1 finding from 1 review
Social functioning · patients with schizophrenia
1 finding from 1 review
Quality of life: 1. General quality of life · patients with schizophrenia
1 finding from 1 review
Satisfaction with treatment: 1. Leaving the study early ‐ long term · patients with schizophrenia
COMPARISON 1: CBT+ STANDARD CARE showed no clear difference in satisfaction with treatment: 1. Leaving the study early ‐ long term compared with STANDARD CARE ALONE (moderate certainty).
1 finding from 1 review
Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) showed no clear difference in global state: non‐responders to the first injection compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (low certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects: movement disorders ‐ EPS during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: movement disorders ‐ EPS during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found